Blog

Did you foresee this £12M cost increase coming?

October sees World Mental Health Day marked and recognised across the globe. The overall objective of the day is to raise awareness of mental health issues and mobilise efforts in support of better mental health. This year’s focus? Mental health in the workplace.

Globally, the WHO reports, “more than 300 million people suffer from depression, the leading cause of disability. More than 260 million are living with anxiety disorders. Many of these people live with both.

The rising costs of mental health disorders

A recent WHO-led study estimates that depression and anxiety disorders cost the global economy US$ 1 trillion each year in lost productivity.” That’s no small sum.

The Guardian reports that 2016 saw the NHS prescribing “a record number of antidepressants, fuelling an upward trend that has seen the number of pills given to patients more than double over the last decade.” (The Guardian)

To demonstrate this, our analysis of the current tariff increase – due to temporary supply issues – of the generic antipsychotic drug Quetiapine (IR) in the UK, shows just how volatile the NHS’s bill for mental health can be.

Quetiapine (IR) in the UK

At-a-glance MarketView analytics

Our interrogative analytics of NHS GP Prescribing Data reveals that the monthly cost to the NHS of Quetiapine (IR)s has risen by over £12M per month in June and July. This ‘temporary’ price concession is still in place now, so the 5 months to October will result in a £50M+ extraordinary cost to the NHS, from just one drug. To put this in context the cost of protecting the whole country from flu with the ‘flu jab’ – costs the NHS around £100M per year.

Inspiremed’s rapid-fire analysis provides valuable insights from NHS and IMS prescription data at the touch of a button. And presents findings in clear easy-to-analyse visualisation dashboards like the one we picture here.

Drill down to key data sets, remove the complexities of data analysis and drive effective sales and marketing activities with real time data.

Book my demonstration

Our sales team use RX Analyser to analyse results and opportunity; it’s used by management to measure performance and identify national trends to drive targeting and strategy.

National Sales Manager, UK Pharmaceutical Company

Comprehensive, flexible, efficient and professional. A recent training program for our sales team was both well delivered and received. Any bespoke amends to the tool are quickly implemented in line with our requirements.

Sales and Marketing Manager, Leading Healthcare Company, 2016

At a CCG level we can show our customers how we can work with individual surgeries to get substantial cost savings and utilise their budgets better. We work with medicines management teams to help them to save money whilst also improving outcomes.

Country Manager UK, Leading Diagnostics Company

Data drives our activity in marketing and sales and Rx Analyser is the perfect tool for this.

Sales and Marketing Manager, Leading Healthcare Company, 2016

Analyser makes drilling down to the information I need to make key marketing decisions simpler and more targeted. Rx Analyser is both functional and elegant and is backed up by the can-do attitude of the Inspiremed team.

Group Product Manager, Leading Pharmaceutical Company

One of the simplest dashboards I have used, this product is very flexible. We use it extensively to gain insight into our business, down to a CCG level.

National Sales Manager, Leading Pharmaceutical Company, 2016

Sign up for added insights